Brepocitinib
Brepocitinib is in Phase 2/3 for alopecia areata, developed by Priovant Therapeutics.
A dual TYK2 and JAK1 inhibitor, approved in the US for dermatomyositis in August 2026, tested in alopecia areata by Pfizer and now in a Phase 2/3 in lichen planopilaris.
- Developed by
- Priovant Therapeutics
- Current phase
- Phase 2/3
- Mechanism
- JAK inhibitor
- Partners
- pfizer
- Indications
- Alopecia areata, Scarring alopecia
- Also known as
- PF-06700841, Lisraya
- Last public activity
- May 2026
- Copy last reviewed
- September 2026
- Record confidence
- Medium
A combined efficacy and confirmatory study.
Calms the immune attack on the follicle by blocking JAK signalling - the class that transformed alopecia areata.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
TYK2 and JAK1 are both JAK-family kinases, so this is a different pair from baricitinib's JAK1/2 or ritlecitinib's JAK3, not a different family; the class trade-off between selectivity and breadth is the argument the whole field is having. Pfizer tested it in a 142-patient Phase 2a in alopecia areata alongside ritlecitinib, published in 2021, and took ritlecitinib forward. Priovant now owns it: the FDA approved it as Lisraya for dermatomyositis in adults on 27 August 2026, with the boxed warning carried by oral JAK inhibitors in the US, and Priovant is running a 342-patient Phase 2b/3 in lichen planopilaris, recruiting since March 2026. An academic Phase 2a in the scarring alopecias completed in 2023. For hair loss it remains investigational everywhere.
Development history
- Phase 2
First Phase 2 trial on record: NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Emma Guttman · n=51 · May 2021
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Pfizer · n=142 · December 2016
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata (Pfizer Phase 2a) — ClinicalTrials.gov
- Brepocitinib in lichen planopilaris, Phase 2/3 (Priovant) — ClinicalTrials.gov
- Dual JAK1/TYK2 inhibitor (brepocitinib) for cicatricial alopecia, investigator-led Phase 2a — ClinicalTrials.gov
- Priovant announces FDA approval of Lisraya (brepocitinib) for adults with dermatomyositis; Phase 2b/3 programme in lichen planopilaris — Company release, August 2026
- FDA approves first oral drug indicated to treat dermatomyositis in adults (Lisraya, brepocitinib) — Regulator filing, August 2026
- Brepocitinib in lichen planopilaris, frontal fibrosing alopecia and central centrifugal cicatricial alopecia: Phase 2a, David et al. — Peer-reviewed, October 2024
- Ritlecitinib and brepocitinib in alopecia areata: Phase 2a results, Guttman-Yassky et al. — Peer-reviewed, December 2021
Related programmes
Other programmes in the register with the same mechanism: JAK inhibitor.
Cite this page
Hair Pipeline, "Brepocitinib — development record", hairpipeline.com/pipeline/brepocitinib-aa